Office Management after Myocardial Infarction
Abstract
Patients should have their modifiable coronary artery risk factors intensively treated after myocardial infarction. Hypertension should be treated with beta-blockers and angiotensin-converting enzyme inhibitors. The blood pressure should be reduced to less than 140/90 mm Hg or to less than 130/80 mm Hg in patients with diabetes or chronic kidney disease. The serum low-density lipoprotein cholesterol should be reduced to less than 70 mg/dL with statins if necessary. Diabetic patients should have their hemoglobin A1c reduced to less than 7.0%. Aspirin or clopidogrel, beta-blockers, and angiotensin-converting enzyme inhibitors should be given indefinitely unless contraindications exist to their use. Long-acting nitrates are effective anti-anginal and anti-ischemic drugs. After an infarction, patients at very high risk for sudden cardiac death should receive an implantable cardioverter-defibrillator. The 2 indications for coronary revascularization are prolongation of life and relief of unacceptable symptoms despite optimal medical management.
Keywords: Angiotensin-converting enzyme inhibitor, Beta-blocker, Coronary risk factors, Myocardial infarction, Statins
To access this article, please choose from the options below
Funding: None.
Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.
Authorship: All authors had access to the data and played a role in writing this manuscript.
PII: S0002-9343(10)00286-X
doi:10.1016/j.amjmed.2010.02.011
© 2010 Elsevier Inc. All rights reserved.

